Wegovy Delivery Rules Eased by MHRA – What Does It Mean for Patients?

05 June, 2026  |  Holy Winter - Healthcare Writer

Wegovy Delivery Rules Eased by MHRA – What Does It Mean for Patients?

Wegovy Delivery Rules Eased by MHRA - What Does It Mean For Patients?

The MHRA has approved flexible cold-chain delivery for Wegovy, making home delivery of the weight-management injection simpler, more reliable, and more discreet than ever before

Birmingham, UK, 5 June 2026 – iQ Doctor, one of the UK's leading online healthcare providers, welcomes a significant regulatory update that will improve access to Wegovy (semaglutide), the once-weekly injectable weight-management treatment, for patients across the UK.

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved an update to the product information for the Wegovy injection, allowing the medication to be transported and delivered at temperatures of up to 30° for up to 48 hours. This marks a meaningful change from the previous requirement for strict cold-chain distribution, where Wegovy had to be kept refrigerated at 2-8° from the point of manufacture all the way to the patient.

As a result, Wegovy has become the first GLP-1 weight-management drug in the UK and Europe to have flexibility around cold-chain delivery, a milestone that opens the door to more reliable, convenient, and discreet home delivery of the medication through pharmacies and online dispensing partners.

Key Facts at a Glance

  • Wegovy (semaglutide injection) can now be delivered at temperatures up to 30° for a 48-hour window during transit.
  • The update was approved by the EMA on 12 April 2026 and shortly followed by a similar decision from the MHRA in the UK.
  • The change applies to the Wegovy injection only, not the oral Wegovy pill, which does not require refrigeration.
  • After first use, patients can continue to store Wegovy injection for up to 28 days below 30°.
  • The update is expected to reduce packaging volume, lower distribution costs, and support discreet home delivery models.

Why this matters for patients

For the millions of people in the UK living with obesity, access to effective, clinically approved treatments has not always been straightforward. Cold-chain logistics have historically imposed limitations on how and when weight-management injections can be dispatched and received, particularly for patients relying on home delivery via online healthcare providers.

This regulatory change directly addresses those barriers. By permitting a 48-hour controlled-temperature delivery window, the update simplifies last-mile logistics, reduces packaging complexity, and ensures that patients can receive their treatment at home with greater reliability and less environmental impact.

The update also reflects a broader shift in how medicines are being distributed, recognising that patients increasingly expect and benefit from direct-to-patient models, particularly for treatments relating to sensitive conditions such as obesity.

What changes for iQ Doctor patients?

For existing and prospective iQ Doctor patients prescribed Wegovy, this update is good news. As the supply chain adapts to the new guidelines, patients can expect more consistent availability, faster dispatch, and improved home delivery reliability, without any change to the safety or efficacy of the medication itself.

iQ Doctor's clinical team continues to follow all MHRA guidance to ensure patients receive treatments that meet the highest standards of quality and safety. The regulatory update does not change how patients use or store Wegovy, once received, it should continue to be stored as instructed by the prescribing clinician or as set out in the patient information leaflet.

About Wegovy

Wegovy (semaglutide) is a GLP-1 receptor agonist approved in both the EU and the UK for long-term weight management in adults with obesity, or in adults who are overweight with at least one weight-related health condition. It is administered as a once-weekly subcutaneous injection and has demonstrated clinically significant reductions in body weight in large-scale clinical trials. Novo Nordisk recently received approval for a higher-dose 7.2 mg version in the EU, providing an additional option for patients who require greater weight reduction.

iQ Doctor offers clinician-led assessment, prescribing and support for patients considering Wegovy and other approved weight-management treatments. All patients undergo a full medical review before any prescription is issued.

"This is genuinely good news for patients who rely on Wegovy as part of their weight-management journey. At iQ Doctor, we have always believed that access to evidence-based treatment should be as simple and dignified as possible. Easing cold-chain delivery requirements removes a real practical barrier, it means we can serve patients more efficiently, more reliably, and with greater discretion. Obesity is a complex, chronic condition, and anything that reduces friction in accessing approved treatment is a step in the right direction."

Omar El Gohary, Chief Executive Officer, iQ Doctor

Interested in clinician-led weight management support? Find out if Wegovy could be right for you. Visit iQ Doctor

About iQ Doctor

iQ Doctor is a UK-based online healthcare provider offering clinician-led consultations, prescriptions, and treatment programmes across a range of conditions including weight management, sexual health, skincare, and mental health. All services are delivered by registered UK clinicians and operate in full compliance with MHRA and General Pharmaceutical Council requirements.

This press release is provided for informational purposes. Wegovy is a prescription-only medicine. Always consult a qualified healthcare professional before starting any new treatment.


Reviewed By

Omar El-Gohary

Omar El-Gohary

CEO & Superintendent Pharmacist, iQ Doctor - Registration Number 2059792.

Omar is passionate about developing healthcare technology to empower our patients.

Related Posts

 | 

Xmas & New Year Delivery Times

 | 

How To Salvage Your Failing New Year’s Resolution

 | 

Metro News


Tags

No Tags Available


Get the latest news